Source: CureToday articles
Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.
Recent Content
- Infusion-Related Reactions: Clinical Trials and Guideline-Driven Prophylaxis and Management Strategies for Patients Undergoing NSCLC Treatment
- Early Challenges in the cGVHD Journey
- Infusion Hesitancy and the Impact of Route of Administration of NSCLC Treatment Options in Patients’ Quality of Life
- Navigating the Path to Second-Line Therapy
- Breaking Down Treatment Variables in AYA Patients With Cancer
- ASCO25 Preview: Key Research Accelerating Cancer Care
- Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care
- Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer
- FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy
- FDA Approves Mepolizumab for Treatment of Patients With COPD and an Eosinophilic Phenotype